ClinicalTrials.gg

Program

Lutetium Lu 177 Ludotadipep

Also written as “[177Lu]Ludotadipep” and “[177-Lu]Ludotadipep”.

Its studies are mostly in Prostatic Neoplasms, led by FutureChem.

Furthest: phase 3, since Apr 15, 20263 company-led studies, 2 open or runningNext primary completion: Mar 26, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
FutureChem32 open or runningphase 3since Apr 15, 2026Jul 7, 2020Mar 26, 2028phase 3 · NCT07853209

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 7, 2020First study: phase 1 study in Prostatic NeoplasmsFirst studyNCT04509557 · 30 enrolled · Korea, Republic of
  2. Oct 6, 2022Phase 2 study in Prostatic NeoplasmsNCT05579184 · 20 enrolled · Korea, Republic of
  3. Apr 15, 2026Phase 3 study in Prostatic NeoplasmsPhase 3 reachedNCT07853209 · 114 planned · South Korea

Ahead

  1. Mar 26, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07853209

TargetBeta

FOLH1 →read by rule
“A radioconjugate composed of ludotadipep, a prostate-specific membrane antigen (PSMA)-targeting agent, ”NCIt, by rule

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22
SHR-4394Jiangsu HengRui Medicinephase 22

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07853209Prostatic Neoplasms · South Korea3RecruitingMar 26, 2028114
NCT05579184Prostatic Neoplasms · Korea, Republic of2Active, not recruitingDec 31, 202420
NCT04509557Prostatic Neoplasms · Korea, Republic of1CompletedJun 30, 202230

How it is read

Names in the registry

  • “[177Lu]Ludotadipep”, 2 entries
  • “[177-Lu]Ludotadipep”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.